C12N 2720/10043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2720/10043 (Viral genome or elements thereof as genetic vector) appears on 2 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 2
- Published applications
- 5
- Assignees
- 3
- Inventors
- 11
- Latest grant
- 19 Mar 2013
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Compositions and methods for the treatment of viral hepatitis19 Mar 2013US 8,398,969 B2HepC Biotechnológiai Kutató és Fejlesztö Kft.
- Method for generating nonpathogenic infectious pancreatic necrosis virus (IPNV) from synthetic RNA transcripts14 Aug 2001US 6,274,147 B1University of Maryland Biotechnology Institute
- Hvt aiv vectors and uses thereof27 Feb 2025US 2025/0064917 A1Boehringer Ingelheim Vetmedica GmbH
- Oncolytic virus based cancer therapy25 Jul 2024US 2024/0245739 A1
- Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients16 Dec 2021US 2021/0386804 A1
- Compositions and methods for the treatment of viral hepatitis26 Nov 2009US 2009/0291063 A1HepC Biotechnológiai Kutató és Fejlesztö Kft.
- Viruses and virus-like particles for multiple antigen and target display8 Jun 2006US 2006/0121468 A1
Most cited
By later US patents